Start the conversation
There's an old adage in business that I know you're familiar with: "You have to spend money to make money."
And after looking at the second-quarter earnings report of our "Liquid Biopsy" play, Trovagene Inc. (Nasdaq: TROV), that's exactly the force at work here.
The small-cap biotech firm reported a loss that was bigger than expected, and that sent shares down nearly 8% today.
This is premium content for Private Briefing subscribers only.